Analyst ratings and price targets can significantly influence a stock's performance. In this case, UBS, a reputable financial institution, has given AtriCure a Buy rating and set a price target of $56. This suggests that UBS sees potential in ATRC, which could encourage investors to buy the stock, potentially driving up its price in the short term.